Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Other Non-Current Liabilities (2019 - 2025)

Vaxcyte (PCVX) has 7 years of Other Non-Current Liabilities data on record, last reported at $100000.0 in Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed 0.0% to $100000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $100000.0, a 0.0% change, with the full-year FY2025 number at $100000.0, changed 0.0% from a year prior.
  • Other Non-Current Liabilities reached $100000.0 in Q4 2025 per PCVX's latest filing, roughly flat from $100000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for PCVX hit a ceiling of $103000.0 in Q1 2021 and a floor of $2000.0 in Q3 2023.
  • A 5-year average of $68769.2 and a median of $93000.0 in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 97.75% in 2023, then changed 0.0% in 2025.
  • Tracing PCVX's Other Non-Current Liabilities over 5 years: stood at $96000.0 in 2021, then tumbled by 90.62% to $9000.0 in 2022, then crashed by 77.78% to $2000.0 in 2023, then soared by 4900.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for PCVX at $100000.0 in Q4 2025, $100000.0 in Q4 2024, and $2000.0 in Q3 2023.